Abstract
Erythropoietin (EPO) has long been utilized for the treatment of renal anemia. The erythropoietin receptor (EPOR) is also expressed in the cardiovascular and central nervous systems in addition to an erythroid lineage, to provide an organoprotective role against several types of cellular stress. Pulmonary hypertension (PH) is a poor prognostic disease caused by primary and secondary pulmonary vascular injury. We observed the effects of EPO derivatives on monocrotaline-induced PH in rats on the supposition that EPO may protect small arteries from injury. Asialoerythropoietin (AEPO) lacks sialic acids in the termini of carbohydrate chains that results in rapid clearance from blood. Carbamyl-erythropoietin (CEPO) interacts with EPOR/βc heterodimers, but not with EPOR homodimers expressed in erythroid cells. Monocrotaline-injected rats were treated with continuous intravenous injection of 2500 ng/kg/day of EPO, AEPO, or CEPO for 21 days, and lung histology, cardiac function, and mRNA expression in the lungs were examined. Wall thickening of small arteries in the lungs and PH were improved by administration of EPO, but not by its non-hematopoietic derivatives, AEPO, or CEPO. Erythropoietin administration increased mRNA expression of...Continue Reading
References
Mar 1, 1992·Journal of Cellular Biochemistry·Y J DongE Goldwasser
Dec 12, 1990·European Journal of Biochemistry·N ImaiN Ochi
Sep 12, 2002·Biochimica Et Biophysica Acta·Paul H Weigel, Jasper H N Yik
Dec 4, 2002·Circulation·Zhao Zhong ChongKenneth Maiese
Apr 19, 2003·Blood·Christopher HeeschenStefanie Dimmeler
May 10, 2003·Lancet·James R Runo, James E Loyd
May 15, 2003·Proceedings of the National Academy of Sciences of the United States of America·Serhat ErbayraktarMichael Brines
Jan 15, 2004·American Journal of Respiratory Medicine : Drugs, Devices, and Other Interventions·Nazzareno GalièAngelo Branzi
Mar 23, 2004·Cardiovascular Pathology : the Official Journal of the Society for Cardiovascular Pathology·Akimitsu NasunoYoshifusa Aizawa
Jun 19, 2004·Blood·Bojana B Beleslin-CokicConstance Tom Noguchi
Jun 24, 2004·Circulation·John H NewmanUNKNOWN National Heart, Lung and Blood Institute/Office of Rare Diseases
Oct 1, 2004·Proceedings of the National Academy of Sciences of the United States of America·Michael BrinesAnthony Cerami
Jan 6, 2005·JAMA : the Journal of the American Medical Association·Kenneth MaieseZhao Zhong Chong
Feb 5, 2005·Circulation Research·Yidan D ZhaoDuncan J Stewart
Jun 9, 2005·Circulation·Olivier SitbonGérald Simonneau
Jul 16, 2005·Cardiovascular Research·Tsuyoshi YoshidaYoshifusa Aizawa
Nov 18, 2005·The New England Journal of Medicine·Nazzareno GalièUNKNOWN Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group
Mar 15, 2006·Circulation·Kimio SatohHiroaki Shimokawa
Apr 11, 2006·Journal of Molecular and Cellular Cardiology·Takuya OzawaYoshifusa Aizawa
Apr 25, 2006·Biochemical and Biophysical Research Communications·Wataru MitsumaYoshifusa Aizawa
Jan 24, 2007·American Journal of Physiology. Heart and Circulatory Physiology·Rachel Zhande, Aly Karsan
Sep 28, 2007·The European Respiratory Journal·M E van AlbadaR G Schoemaker
Jan 11, 2008·Journal of the American Society of Nephrology : JASN·Yukiyo YokomakuAtsunori Kashiwagi
Oct 27, 2009·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Christophe LancrinGeorges Lacaud
Mar 27, 2010·Journal of Biomedicine & Biotechnology·S UmarA van der Laarse
Dec 7, 2010·Heart and Vessels·Sung-A ChangDuk-Kyung Kim
Jan 7, 2011·Heart and Vessels·Alisa LimsuwanSuradej Hongeng
Citations
Oct 31, 2012·International Journal of Molecular Sciences·Kenneth MaieseShaohui Wang
Mar 30, 2013·International Immunopharmacology·Li-Qing BiWei-Ping Xie
May 6, 2015·Molecular Medicine Reports·Rong ZhuZi-Li Meng
Jul 10, 2014·Pulmonary Circulation·Victor SamillanLouise Ostergaard
Apr 27, 2018·Arteriosclerosis, Thrombosis, and Vascular Biology·Kimio Satoh, Hiroaki Shimokawa
Jun 28, 2016·Molecular and Cellular Biochemistry·Eva MalikovaJan Klimas